Elutia Inc. Net Assets
Elutia Inc. net assets. Based on the latest financial reports, Elutia Inc. (ELUT) has net assets worth $15.75 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($43.65 Million) and total liabilities ($27.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Elutia Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.75 Million |
| % of Total Assets | 36.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | 104.66% |
| 10-Year Change | N/A |
| Growth Volatility | 51.07 |
Net Assets of Elutia Inc. (2018–2025)
Net assets of Elutia Inc. from 2018 to 2025. This chart illustrates how Elutia Inc.'s net assets have evolved over time, based on quarterly financial data. See ELUT equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Elutia Inc. (2018–2025)
The table below shows the annual net assets of Elutia Inc. from 2018 to 2025. For live market cap and overall valuation, see ELUT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.67 Million | +159.82% |
| 2024-12-31 | $-46.26 Million | -19.84% |
| 2023-12-31 | $-38.60 Million | -666.94% |
| 2022-12-31 | $-5.03 Million | -137.22% |
| 2021-12-31 | $13.52 Million | -35.09% |
| 2020-12-31 | $20.83 Million | +137.80% |
| 2019-12-31 | $-55.11 Million | -26.97% |
| 2018-12-31 | $-43.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elutia Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13121400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Elutia Inc. Net Assets Breakdown (December 2025)
Elutia Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $43.00K | 0.16% |
| Other Components | $203.84 Million | 736.64% |
| Total Equity | $27.67 Million | 100.00% |
Elutia Inc. Competitors by Market Cap
The table below lists competitors of Elutia Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harn Engineering Solutions Public Company Limited
BK:HARN
|
$35.89 Million |
|
biote Corp
NASDAQ:BTMD
|
$35.89 Million |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
$35.90 Million |
|
Buima Group
TWO:5543
|
$35.90 Million |
|
JCH Systems Inc
KQ:033320
|
$35.85 Million |
|
GP Petroleums Limited
NSE:GULFPETRO
|
$35.83 Million |
|
Salter Brothers Emerging Companies Ltd
AU:SB2
|
$35.82 Million |
|
AGRONOMICS LTD.LS-0000001
F:V77
|
$35.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elutia Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -46,260,000 to 27,672,000, a change of 73,932,000.
- Net income of 53,380,000 contributed positively to equity growth.
- New share issuances of 13,795,000 increased equity.
- Other factors increased equity by 6,757,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $53.38 Million | +192.9% |
| Share Issuances | $13.79 Million | +49.85% |
| Other Changes | $6.76 Million | +24.42% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Elutia Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-4.07 | $0.81 | x |
| 2019-12-31 | $-5.17 | $0.81 | x |
| 2020-12-31 | $2.04 | $0.81 | x |
| 2021-12-31 | $1.29 | $0.81 | x |
| 2022-12-31 | $-0.36 | $0.81 | x |
| 2023-12-31 | $-2.13 | $0.81 | x |
| 2024-12-31 | $-1.59 | $0.81 | x |
| 2025-12-31 | $0.60 | $0.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elutia Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 192.90%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 434.23%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 2.25x
- Recent ROE (192.90%) is above the historical average (-11.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -29.63% | 0.82x | 0.00x | $-7.23 Million |
| 2019 | 0.00% | -27.83% | 0.96x | 0.00x | $-6.43 Million |
| 2020 | -104.77% | -51.13% | 0.52x | 3.98x | $-23.91 Million |
| 2021 | -183.66% | -52.40% | 0.71x | 4.97x | $-26.18 Million |
| 2022 | 0.00% | -137.94% | 0.35x | 0.00x | $-32.39 Million |
| 2023 | 0.00% | -152.18% | 0.57x | 0.00x | $-33.80 Million |
| 2024 | 0.00% | -221.33% | 0.67x | 0.00x | $-49.32 Million |
| 2025 | 192.90% | 434.23% | 0.20x | 2.25x | $50.61 Million |
Industry Comparison
This section compares Elutia Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elutia Inc. (ELUT) | $15.75 Million | 0.00% | 1.77x | $35.87 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more